Product Information for Velcade - Therapeutic Goods Administration
... patients with multiple myeloma, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/mL respectively. In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106ng/mL for the 1.0mg/m 2 dose and 89 to 120ng/mL for the 1.3mg/m2 dose. The mean el ...
... patients with multiple myeloma, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/mL respectively. In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106ng/mL for the 1.0mg/m 2 dose and 89 to 120ng/mL for the 1.3mg/m2 dose. The mean el ...
Novel approaches to the development of targeted therapeutic
... (phase I) and 90 patients (ALLEVIATE-1/2 trials) [21] with active lupus disease following Epratuzumab treatment. Epratuzumab was well tolerated without severe adverse events [21]. A 12-week phase IIb (EMBLEM) randomized, double-blind, placebo-controlled multicenter study was further conducted with E ...
... (phase I) and 90 patients (ALLEVIATE-1/2 trials) [21] with active lupus disease following Epratuzumab treatment. Epratuzumab was well tolerated without severe adverse events [21]. A 12-week phase IIb (EMBLEM) randomized, double-blind, placebo-controlled multicenter study was further conducted with E ...
ACTEMRA Product Monograph
... histoplasmosis, coccidiomycosis, listeriosis). Patients have presented with disseminated rather than localized disease. Rheumatoid arthritis itself as well as concomitant immunosuppressant treatment such as methotrexate or corticosteroids are additional risk factors for serious infections. Patients ...
... histoplasmosis, coccidiomycosis, listeriosis). Patients have presented with disseminated rather than localized disease. Rheumatoid arthritis itself as well as concomitant immunosuppressant treatment such as methotrexate or corticosteroids are additional risk factors for serious infections. Patients ...
A Stepwise Approach to Management of Stable
... stable COPD and at producing bronchodilation in patients who lacked prior response to SABAs.9,29,31 Several randomized controlled trials (RCTs) compared at least 4 weeks of treatment with ipratropium alone or in combination with SABAs in almost 4,000 patients with stable COPD.15,32-39 Ipratropium sh ...
... stable COPD and at producing bronchodilation in patients who lacked prior response to SABAs.9,29,31 Several randomized controlled trials (RCTs) compared at least 4 weeks of treatment with ipratropium alone or in combination with SABAs in almost 4,000 patients with stable COPD.15,32-39 Ipratropium sh ...
Formoterol as relief medication in asthma: a worldwide safety and
... of days incapacity due to asthma, and changes in concomitant asthma medication were recorded in the notebook for the entire 6 months. Patients were contacted by telephone to remind them to record daily symptoms and use of study medication during the 2 weeks preceding each scheduled clinic visit. At ...
... of days incapacity due to asthma, and changes in concomitant asthma medication were recorded in the notebook for the entire 6 months. Patients were contacted by telephone to remind them to record daily symptoms and use of study medication during the 2 weeks preceding each scheduled clinic visit. At ...
EAPCCT 2013, Copenhagen, Denmark
... Occupational and Environmental Medicine, University of Aarhus, Denmark ...
... Occupational and Environmental Medicine, University of Aarhus, Denmark ...
Ataxia - Diagnostic Centers of America
... severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical conse ...
... severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical conse ...
DOI: 10.1111/hiv.12119 _________________________________________________________________________________________________________________________ HIV Medicine
... recommendation, where the risks and benefits are more closely balanced or are more uncertain. Most clinicians and patients would want to follow a weak or conditional recommendation but many would not. Alternative approaches or strategies may be reasonable depending on the individual patient’s circum ...
... recommendation, where the risks and benefits are more closely balanced or are more uncertain. Most clinicians and patients would want to follow a weak or conditional recommendation but many would not. Alternative approaches or strategies may be reasonable depending on the individual patient’s circum ...
Labetalol Hydrochloride
... any signs or symptoms of impending cardiac failure or hepatic dysfunction (see WARNINGS). Also, transient scalp tingling may occur, usually when treatment with labetalol tablets is initiated (see ADVERSE REACTIONS). Laboratory Tests Routine laboratory tests are ordinarily not required before or aft ...
... any signs or symptoms of impending cardiac failure or hepatic dysfunction (see WARNINGS). Also, transient scalp tingling may occur, usually when treatment with labetalol tablets is initiated (see ADVERSE REACTIONS). Laboratory Tests Routine laboratory tests are ordinarily not required before or aft ...
Severe hyperkalemia requiring hospitalization: predictors of
... Introduction: Severe hyperkalemia, with potassium (K+) levels ≥ 6.5 mEq/L, is a potentially life-threatening electrolyte imbalance. For prompt and effective treatment, it is important to know its risk factors, clinical manifestations, and predictors of mortality. Methods: An observational cohort stu ...
... Introduction: Severe hyperkalemia, with potassium (K+) levels ≥ 6.5 mEq/L, is a potentially life-threatening electrolyte imbalance. For prompt and effective treatment, it is important to know its risk factors, clinical manifestations, and predictors of mortality. Methods: An observational cohort stu ...
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
... [1], and the first recorded patient treated with amphotericin received the drug in 1957, because of CPA complicating tuberculosis (TB) [2]. The first radiological description of aspergilloma was in France, in 1938, and was described as a “mega-mycetome intra-bronchiectasique” [3]. The middle of the ...
... [1], and the first recorded patient treated with amphotericin received the drug in 1957, because of CPA complicating tuberculosis (TB) [2]. The first radiological description of aspergilloma was in France, in 1938, and was described as a “mega-mycetome intra-bronchiectasique” [3]. The middle of the ...
Molluscum Contagiosum and Warts - American Academy of Family
... N), and imiquimod are approved for genital HPV. In addition to case reports, one study23 of 50 patients showed a 56 percent clearance rate with imiquimod. Imiquimod is more rapidly being adopted into clinical practice because of its easy application. It may be useful in nongenital HPV, but more stud ...
... N), and imiquimod are approved for genital HPV. In addition to case reports, one study23 of 50 patients showed a 56 percent clearance rate with imiquimod. Imiquimod is more rapidly being adopted into clinical practice because of its easy application. It may be useful in nongenital HPV, but more stud ...
Tourette*s syndrome
... • have had tics for at least a year. The tics can occur many times a day (usually in bouts) nearly every day, or off and on. • have tics that begin before he or she is 18 years of age. • have symptoms that are not due to taking medicine or other drugs or due to having another medical condition (for ...
... • have had tics for at least a year. The tics can occur many times a day (usually in bouts) nearly every day, or off and on. • have tics that begin before he or she is 18 years of age. • have symptoms that are not due to taking medicine or other drugs or due to having another medical condition (for ...
Practice Guidelines (8th Edition) Chest Physicians Evidence
... This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation inten ...
... This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation inten ...
DuoDote® (atropine and pralidoxime chloride injection) Auto
... A potential hazardous effect of atropine is inhibition of sweating which, in a warm environment or with exercise, can lead to hyperthermia and heat injury. The elderly and children may be more susceptible to the effects of atropine. PRECAUTIONS General: The desperate condition of the organophosphoro ...
... A potential hazardous effect of atropine is inhibition of sweating which, in a warm environment or with exercise, can lead to hyperthermia and heat injury. The elderly and children may be more susceptible to the effects of atropine. PRECAUTIONS General: The desperate condition of the organophosphoro ...
1 Chapter 156: Acute Otitis Media and Otitis Media with Effusion
... cystic fibrosis. The genetic factors of otitis media have yet to be delineated, even though it is well known that OM occurs more frequently in certain families. Treatment of OM varies worldwide with divergent results from numerous studies and clinical trials. The indications for therapy, in particul ...
... cystic fibrosis. The genetic factors of otitis media have yet to be delineated, even though it is well known that OM occurs more frequently in certain families. Treatment of OM varies worldwide with divergent results from numerous studies and clinical trials. The indications for therapy, in particul ...
Christian Jackisch
... Importance of side effects in the treatment of breast cancer Patients with breast cancer can expect to receive multiple lines ...
... Importance of side effects in the treatment of breast cancer Patients with breast cancer can expect to receive multiple lines ...
K Kawasaki disease: Etiology, pathogenesis, and treatment
... with narrowed lumens and calcified arterial walls, despite the fact that these changes may not be apparent on arteriography.15 Therapy with IVIG has decreased the incidence of giant aneurysms,12 which rarely regress and frequently develop complicating thromboses, stenosis, or total occlusion. Myocar ...
... with narrowed lumens and calcified arterial walls, despite the fact that these changes may not be apparent on arteriography.15 Therapy with IVIG has decreased the incidence of giant aneurysms,12 which rarely regress and frequently develop complicating thromboses, stenosis, or total occlusion. Myocar ...
Applicant Submitted Proposed Protocol - Word 1976 KB
... Asthma is a chronic respiratory disease, affecting approximately one in ten of the general population in Australia (ACAM 2011). By international standards, the prevalence of asthma in Australia is high and particularly common amongst indigenous Australians. The disease is characterised by inflammati ...
... Asthma is a chronic respiratory disease, affecting approximately one in ten of the general population in Australia (ACAM 2011). By international standards, the prevalence of asthma in Australia is high and particularly common amongst indigenous Australians. The disease is characterised by inflammati ...
COPD and Asthma
... practitioners are these days encouraged, from several quarters, to screen their smoking patients for early COPD. Smoking cessation is still the only available treatment that indisputably improves the long-term prognosis of this disease. ...
... practitioners are these days encouraged, from several quarters, to screen their smoking patients for early COPD. Smoking cessation is still the only available treatment that indisputably improves the long-term prognosis of this disease. ...
Guidance for the prevention, testing, treatment and management of
... latest estimates on the number of adults infected with hepatitis C showed there were around 231,000 in 2003. Many of these infected people do not realise they have the virus as it can take years or even decades for symptoms to appear. Early treatment, however, is effective at clearing the virus in t ...
... latest estimates on the number of adults infected with hepatitis C showed there were around 231,000 in 2003. Many of these infected people do not realise they have the virus as it can take years or even decades for symptoms to appear. Early treatment, however, is effective at clearing the virus in t ...
Chapter 21. Pain Medical Treatment Guidelines Subchapter A
... with chronic pain. This classification system may not address the psychological and psychosocial issues that occur in the perception of pain, suffering, and disability and may require referral to psychiatric or psychological clinicians. These issues should be documented with preference to the diagno ...
... with chronic pain. This classification system may not address the psychological and psychosocial issues that occur in the perception of pain, suffering, and disability and may require referral to psychiatric or psychological clinicians. These issues should be documented with preference to the diagno ...
Queen`s University Belfast - Research Portal
... Background: Adherence to treatment is often reported to be low in children with cystic fibrosis. Adherence in cystic fibrosis is an important research area and more research is needed to better understand family barriers to adherence in order for clinicians to provide appropriate intervention. The a ...
... Background: Adherence to treatment is often reported to be low in children with cystic fibrosis. Adherence in cystic fibrosis is an important research area and more research is needed to better understand family barriers to adherence in order for clinicians to provide appropriate intervention. The a ...
OCT in Diabetic Macular Edema
... Macular edema is defined as a focal or diffuse area of retinal thickening which may or may not be associated with hard exudates. Depending on its location and size it can either a clinically significant or non-significant. A number of clinical methods and investigations have been used for long for t ...
... Macular edema is defined as a focal or diffuse area of retinal thickening which may or may not be associated with hard exudates. Depending on its location and size it can either a clinically significant or non-significant. A number of clinical methods and investigations have been used for long for t ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.